Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma

Journal of Medical Virology

Volumn 50, Issue 4, 1996, Pages 293-302

  Coste, Joliette ^a   Montes, Brigitte ^a   Reynes, Jacques ^a   Peeters, Martine ^b   Segarra, Christiane ^a   Vendrell, Jean Pierre ^a   Delaporte, Eric ^b   Segondy, Michel ^a,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UR36   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

Amplicor; bDNA; HIV 1; NASBA; Viral load

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS;

CD4 LYMPHOCYTE COUNT; EVALUATION STUDIES; GENETIC TECHNIQUES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIREMIA; VIROLOGY;

HIV 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029808412     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199612)50:4<293::AID-JMV3>3.0.CO;2-3     Document Type: Article

References (33)

1. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, Van der Noordaa J (1990): Rapid and simple method for purification of nucleic acids. Journal of Clinical Microbiology 28:495-503.
2. Cao Y, Qin L, Zhang L, Safrit J, Ho DD (1995): Virologic and immunologic characterization of long term survivors of human immunodeficiency virus type 1 infection. New England Journal of Medicine 332:202-208.
3. Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartletti JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Fauci AS (1995): Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proceedings of the National Academy of Sciences of the USA 92:6017-6021.
4. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rübsamen-Waigmann H, Mullins JI (1993): Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 262:1257-1261.
5. Dewar RL, Highbarger HC, Sarmiento MD, Todd JA, Vasudevachari MB, Davey RT, Kovacs JA, Salzman NP, Lane HC, Urdea MS (1994): Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. Journal of Infectious Diseases 170:1172-1179.
6. Henrard DR, Phillips JF, Muenz LR, Blattner WA, Wiesner D, Eyster ME, Goedert JJ (1995): Natural history of HIV-1 cell-free viremia. Journal of the American Medical Association 274:554-558.
7. Hogervorst E, Jurrians S, de Wolf F, van Wijk A, Wiesma A, Valk M, Roos M, van Gemen B, Coutinho R, Miedema F, Goudsmit J (1995): Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. Journal of Infectious Diseases 171: 811-821.
8. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, Merigan TC (1991): Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. Journal of Infectious Diseases 163:862-866.
9. Jackson JB, Kwok SY, Sninsky JJ, Hopsicker JS, Sannerud KJ, Rhame FS, Henry K, Simpson M, Balfour (Jr) HH (1990): Human immunodeficiency virus detected in all seropositive symptomatic and asymptomatic individuals. Journal of Clinical Microbiology 28:16-19.
10. Kaiser L, Perrin L, Hirschel B, Furrer H, Von Overbeak J, Olmain M, Yerly S (1995): Foscarnet decreases human immunodeficiency virus RNA. Journal of Infectious Diseases 172:225-227.
11. Koshida R, Vrang L, Gilljam G, Harmemberg J, Oberg B, Wahren B (1989): Inhibition of human immunodeficiency virus in vitro by combination of 3′-azido-3′-deoxy-thymidine and foscarnet. Antimicrobials Agents and Chemotherapy 33:778-780.
12. Lin HJ, Myers LE, Yen-Lieberman B, Hollinger FB, Henrard D, Hooper CJ, Kokka R, Kwok S, Rasheed S, Vahey M, Winters MA, McQuay LJ, Nara PL, Reicherderfer P, Coombs RW, Jackson JB (1994): Multicenter evaluation of quantitation method for plasma human immunodeficiency virus type 1 RNA. Journal of Infectious Diseases 170:553-562.
13. Loussert-Ajaka I, Descamps D, Simon F, Brun-Vézinet F, Ekwalanga M, Saragosti S (1995): Genetic diversity and HIV detection by polymerase chain reaction. Lancet 346:912-913.
14. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe V, Weller IVD, Tedder RS (1995): HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 345:820-824.
15. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P (1995): Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 122:573-579.
16. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA (1996): Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
17. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S (1994): Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. Journal of Clinical Microbiology 32:292-300.
18. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD, and the Veterans Affairs Cooperative Study Group on AIDS (1996): Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New England Journal of Medicine 334:426-431.
19. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong S-J, Stempien M, Hoo B, Besemer D, Yeghiazarian T, Irvine B, Kolberg J, Kokka R, Neuwald P, Urdea MS (1994): Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 8:446-454.
20. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Desmarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, Margolick JB, Buchbinder S, Giorgi JV, Fauci AS (1995): Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. New England Journal of Medicine 332:209-216.
21. Piatack (Jr) M, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk K-C, Hahn BH, Shaw GM, Lifson JD (1993): High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
22. Reddy MM, Grieco MH, McKinley GF, Causey DM, van der Horst CM, Parenti DM, Hooton TM, Davis RB, Jacobson MA (1992): Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. Journal of Infectious Diseases 166:607-610.
23. Revets H, Marissens D, De Wit S, Lacor P, Clumeck N, Lauwers S, Zissis G (1996): Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV Monitor, and QUANTIPLEX HIV RNA Asasy, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. Journal of Clinical Microbiology 34:1058-1064,
24. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J, Boucher CAB (1995): Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus population in persons treated with lamivudine (3TC). Journal of Infectious Diseases 171:1411-1419.
25. Semple M, Loveday C, Weller I, Tedder R (1991): Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. Journal of Medical Virology 35:38-45.
26. Shafer RW, Iversen AKN, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC, and the AIDS Clinical Trials Group 143 Virology Team (1995): Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. Journal of Infectious Diseases 172:70-78.
27. Todd J, Pachl C, White R, Yeghiazarian T, Johnson P, Taylor B, Holodniy M, Kern D, Hamren S, Chernoff D, Urdea M (1995): Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 10 (suppl. 2)S35-S44.
28. Todd J, Yeghiazarian T, Hoo B, Detmer J, Kolberg J, White R, Wilber J, Urdea M (1994): Quantitation of human immunodeficiency virus plasma RNA by branched DNA and reverse transcription coupled polymerase chain reaction assay method: a critical evaluation of accuracy and reproducibility. Serodiagnosis and Immunotherapy in Infectious Disease 6:233-239.
29. van Gemen B, Kievits T, Nara P, Huisman HG, Jurriaans S, Goudsmit J, Lens P (1993a): Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 7(suppl. 2):S107-S110.
30. van Gemen B, Kievits T, Schukkink R, van Strijp D, Malek LT, Sooknanan R, Huisman HG, Lens P (1993b): Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. Journal of Virological Methods 43:177-187.
31. van Kerckhoven I, Fransen K, Peeters M, de Beenhouwer H, Piot P, van der Groen G (1994): Quantitation of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection. Journal of Clinical Microbiology 32:1669-1673.
32. Verhofstede C, Reniers S, van Wanzeele F, Plum J (1994). Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS 8:1421-1427.
33. Winters MA, Tan LB, Katzenstein DA, Merigan TC (1993): Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. Journal of Clinical Microbiology 31:2960-2966.